Polpharma Files for EU Approval of Tysabri Biosimilar

July 18th, 2022|Categories: Featured, Industry News|Tags: , , , |

Polpharma Biologics has filed for approval in the EU for its biosimilar of Tysabri, Biogen’s multiple sclerosis (MS) therapy. The application is the first of its kind in the EU, and covers the intravenous version of the drug. Biogen originally had 5 more years of exclusivity, but a key patent for the drug was revoked in a European court last year.

Go to Top